Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma

BACKGROUND: No biomarkers have been established to predict treatment efficacy in renal cell carcinoma (RCC). In an exploratory retrospective analysis of a Phase 2 study, we constructed composite biomarker scores (CBSs) to predict progression-free survival (PFS) and overall survival (OS) in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chung-Han, Motzer, Robert J., Glen, Hilary, Michaelson, M. D., Larkin, James, Minoshima, Yukinori, Kanekiyo, Michio, Ikezawa, Hiroki, Sachdev, Pallavi, Dutcus, Corina E., Funahashi, Yasuhiro, Voss, Martin H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782770/
https://www.ncbi.nlm.nih.gov/pubmed/33024271
http://dx.doi.org/10.1038/s41416-020-01092-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782770/
https://www.ncbi.nlm.nih.gov/pubmed/33024271
http://dx.doi.org/10.1038/s41416-020-01092-0

Ejemplares similares